Phio Pharmaceuticals (NASDAQ:PHIO) Stock Price Up 2.5%

Phio Pharmaceuticals Corp. (NASDAQ:PHIOGet Free Report) rose 2.5% during trading on Thursday . The company traded as high as $0.75 and last traded at $0.74. Approximately 10,152 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 298,217 shares. The stock had previously closed at $0.72.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Phio Pharmaceuticals in a report on Tuesday, May 14th.

Read Our Latest Report on Phio Pharmaceuticals

Phio Pharmaceuticals Trading Up 2.5 %

The stock’s 50-day moving average is $0.73 and its 200-day moving average is $0.78. The stock has a market cap of $3.39 million, a price-to-earnings ratio of -0.23 and a beta of 1.40.

Phio Pharmaceuticals (NASDAQ:PHIOGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.47) earnings per share (EPS) for the quarter. On average, equities analysts predict that Phio Pharmaceuticals Corp. will post -1.82 earnings per share for the current fiscal year.

Phio Pharmaceuticals Company Profile

(Get Free Report)

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells.

Recommended Stories

Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.